Intuitive Surgical, Inc. $ISRG Shares Purchased by Annex Advisory Services LLC

Annex Advisory Services LLC boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,143 shares of the medical equipment provider’s stock after purchasing an additional 3,092 shares during the period. Annex Advisory Services LLC’s holdings in Intuitive Surgical were worth $36,328,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. McGuire Investment Group LLC lifted its position in shares of Intuitive Surgical by 0.3% during the 4th quarter. McGuire Investment Group LLC now owns 23,989 shares of the medical equipment provider’s stock valued at $13,586,000 after acquiring an additional 69 shares during the period. Monument Capital Management acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at approximately $209,000. Bridgewater Advisors Inc. lifted its position in shares of Intuitive Surgical by 5.4% during the 4th quarter. Bridgewater Advisors Inc. now owns 1,042 shares of the medical equipment provider’s stock valued at $546,000 after acquiring an additional 53 shares during the period. Bingham Private Wealth LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at approximately $1,088,000. Finally, Sunpointe LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at approximately $267,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity

In other Intuitive Surgical news, VP Fredrik Widman sold 133 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total value of $65,829.68. Following the completion of the sale, the vice president directly owned 660 shares of the company’s stock, valued at approximately $326,673.60. The trade was a 16.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 645 shares of Intuitive Surgical stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $485.01, for a total transaction of $312,831.45. Following the completion of the sale, the senior vice president directly owned 1,613 shares of the company’s stock, valued at $782,321.13. The trade was a 28.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,943 shares of company stock valued at $17,279,568 over the last quarter. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ISRG. Sanford C. Bernstein lifted their price target on shares of Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Zacks Research cut shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Wall Street Zen cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Truist Financial raised their price objective on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Evercore dropped their price objective on shares of Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating for the company in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $604.73.

Intuitive Surgical Price Performance

Shares of ISRG opened at $467.22 on Wednesday. The firm has a 50 day simple moving average of $480.16 and a 200-day simple moving average of $514.98. Intuitive Surgical, Inc. has a 1-year low of $427.84 and a 1-year high of $603.88. The stock has a market cap of $165.92 billion, a price-to-earnings ratio of 59.22, a price-to-earnings-growth ratio of 3.58 and a beta of 1.68.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, topping the consensus estimate of $2.27 by $0.26. The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. Intuitive Surgical’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.21 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.